NO993804L - Farmasoeytiske blandinger av pinnsvin-proteiner og anvendelse derav - Google Patents

Farmasoeytiske blandinger av pinnsvin-proteiner og anvendelse derav

Info

Publication number
NO993804L
NO993804L NO993804A NO993804A NO993804L NO 993804 L NO993804 L NO 993804L NO 993804 A NO993804 A NO 993804A NO 993804 A NO993804 A NO 993804A NO 993804 L NO993804 L NO 993804L
Authority
NO
Norway
Prior art keywords
ions
hedgehog proteins
pharmaceutical mixtures
pharmaceutical
mixtures
Prior art date
Application number
NO993804A
Other languages
English (en)
Norwegian (no)
Other versions
NO993804D0 (no
Inventor
Apollon Papadimitriou
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP98114851A external-priority patent/EP0987028A1/fr
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO993804D0 publication Critical patent/NO993804D0/no
Publication of NO993804L publication Critical patent/NO993804L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
NO993804A 1998-08-07 1999-08-06 Farmasoeytiske blandinger av pinnsvin-proteiner og anvendelse derav NO993804L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98114851A EP0987028A1 (fr) 1998-08-07 1998-08-07 Compositions pharmaceutiques comprennant des hedgehog-proteines et leur utilisation
EP98116734 1998-09-03

Publications (2)

Publication Number Publication Date
NO993804D0 NO993804D0 (no) 1999-08-06
NO993804L true NO993804L (no) 2000-02-08

Family

ID=26149508

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993804A NO993804L (no) 1998-08-07 1999-08-06 Farmasoeytiske blandinger av pinnsvin-proteiner og anvendelse derav

Country Status (15)

Country Link
US (1) US6207718B1 (fr)
EP (1) EP0978285B1 (fr)
JP (1) JP3567103B2 (fr)
CN (1) CN1244429A (fr)
AT (1) ATE310531T1 (fr)
AU (1) AU761341B2 (fr)
CA (1) CA2279743C (fr)
DE (1) DE69928472T2 (fr)
DK (1) DK0978285T3 (fr)
ES (1) ES2253851T3 (fr)
HK (1) HK1025740A1 (fr)
HU (1) HUP9902655A3 (fr)
IL (1) IL131238A (fr)
MA (1) MA26667A1 (fr)
NO (1) NO993804L (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL136230A0 (en) * 1997-11-28 2001-05-20 Roche Diagnostics Gmbh An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes
US6897297B1 (en) * 1997-12-03 2005-05-24 Curis, Inc. Hydrophobically-modified protein compositions and methods
EP0953576B1 (fr) * 1998-04-30 2005-11-02 Curis, Inc. Conjugué de protéine hedgehog active, procédé pour sa production et utilisation
EP1025861A1 (fr) * 1999-02-04 2000-08-09 Roche Diagnostics GmbH Compositions pharmaceutiques des Proteines Hedgehog rendues hydrophobes, et leur utilisation
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
CA2280925A1 (fr) * 1999-07-29 2001-01-29 Bernard Charles Sherman Cefuroxime axetil stabilise
AU2001255767A1 (en) * 2000-04-28 2001-11-12 Curis, Inc. Methods and reagents for tissue engineering of cartilage in vitro
EP1947116B1 (fr) 2003-02-10 2017-06-21 2-BBB Medicines B.V. Acides nucléiques exprimés par action différentielle dans la barrière hématoencéphalique sous des conditions inflammatoires
US20070053883A1 (en) * 2003-03-25 2007-03-08 The Johns Hopkins University Neuronal cell lineages and methods of production thereof
US20070148144A1 (en) * 2005-10-27 2007-06-28 Mason James M Gene-enhanced tissue engineering
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
WO2008118013A2 (fr) 2007-03-23 2008-10-02 To-Bbb Holding B.V. Administration intracellulaire ciblée d'agents antiviraux
JP5362715B2 (ja) * 2007-06-29 2013-12-11 アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー 高温で使用するためのgdf−5を含む液体タンパク質製剤
US7678764B2 (en) * 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
EP2187932B1 (fr) * 2007-08-07 2015-01-28 DePuy Synthes Products, LLC Formules protéiniques comprenant le facteur gdf-5 dans une solution aqueuse acide
WO2009129101A1 (fr) * 2008-04-14 2009-10-22 Advanced Technologies And Regenerative Medicine, Llc Formulations liquides tamponnées de gdf-5
WO2010087702A1 (fr) 2009-01-30 2010-08-05 Stichting Katholieke Universiteit Gène tet2 en tant que marqueur pour diagnostiquer un syndrome myélodysplasique (mds) ou une leucémie myéloïde aiguë (aml) et déterminer le pronostic chez un sujet
WO2011034421A1 (fr) 2009-09-16 2011-03-24 Stichting Het Nederlands Kanker Instituut Gènes cibles fra-1 utilisés comme cibles médicamenteuses pour le traitement du cancer
EP2305717A1 (fr) 2009-09-21 2011-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Inhibition du TNIK pour le traitement du cancer du côlon
EP2608802B1 (fr) 2010-08-27 2017-02-22 Pantarhei Bioscience B.V. Procédé immunothérapeutique pour le traitement du cancer de la prostate
EP2465928A1 (fr) 2010-12-16 2012-06-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Traitement des maladies liées au Th17
US11633458B2 (en) 2013-11-08 2023-04-25 University Of Virginia Patent Foundation Compositions and methods for treating melanoma
WO2016080830A2 (fr) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Procédé immunothérapeutique pour le traitement du cancer du pancréas
CN110248648B (zh) * 2016-11-16 2023-02-24 艾维塔生物医学公司 细胞膜结合信号因子的应用
KR20200103660A (ko) * 2017-11-16 2020-09-02 에이비타 바이오메디컬, 인크. 세포막 결합된 신호전달 인자의 용도

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148901A (en) 1983-10-04 1985-06-05 Johnson & Johnson Protein/polysaccharide complexes
JPH0725689B2 (ja) 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
US5078997A (en) 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5156623A (en) 1990-04-16 1992-10-20 Olympus Optical Co., Ltd. Sustained release material and method of manufacturing the same
US5416071A (en) 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
DE4126983A1 (de) 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5789543A (en) 1993-12-30 1998-08-04 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins and uses related thereto
CA2179029C (fr) * 1993-12-30 2009-02-24 Philip W. Ingham Proteines de type herisson induisant une structure embryonnaire chez les vertebres
JPH09509574A (ja) * 1994-02-25 1997-09-30 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 脊索によって発現されるヘッジホッグ、Vhh−1、の脊椎動物相同体をコードするDNA、及びこれらの使用
US5663390A (en) 1996-08-29 1997-09-02 Libbey-Owens-Ford Co. Method of producing organo indium chlorides
JPH10194987A (ja) * 1997-01-14 1998-07-28 Youtai Iwamoto 骨・軟骨形成用組成物
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
EP0947201B1 (fr) 1998-02-04 2006-06-28 Curis, Inc. Compositions pharmaceutiques contenant des protéines Hedgehog, et leur utilisation
EP0953576B1 (fr) 1998-04-30 2005-11-02 Curis, Inc. Conjugué de protéine hedgehog active, procédé pour sa production et utilisation
EP0953575A1 (fr) 1998-04-30 1999-11-03 Boehringer Mannheim Gmbh Conjugué de proteine hedgehog active, procédé pour sa production et utilisation

Also Published As

Publication number Publication date
NO993804D0 (no) 1999-08-06
CN1244429A (zh) 2000-02-16
CA2279743A1 (fr) 2000-02-07
HU9902655D0 (en) 1999-10-28
EP0978285B1 (fr) 2005-11-23
EP0978285A1 (fr) 2000-02-09
IL131238A0 (en) 2001-01-28
MA26667A1 (fr) 2004-12-20
ATE310531T1 (de) 2005-12-15
DK0978285T3 (da) 2006-03-27
HUP9902655A3 (en) 2000-12-28
AU4344899A (en) 2000-03-02
US6207718B1 (en) 2001-03-27
IL131238A (en) 2005-07-25
HK1025740A1 (en) 2000-11-24
DE69928472T2 (de) 2006-08-10
JP3567103B2 (ja) 2004-09-22
CA2279743C (fr) 2005-05-10
JP2000063283A (ja) 2000-02-29
HUP9902655A2 (hu) 2000-08-28
AU761341B2 (en) 2003-06-05
ES2253851T3 (es) 2006-06-01
DE69928472D1 (de) 2005-12-29

Similar Documents

Publication Publication Date Title
NO993804L (no) Farmasoeytiske blandinger av pinnsvin-proteiner og anvendelse derav
BR0202278A (pt) Dispositivos e processos para a colheita de células
BR0017013A (pt) Composições de antibiótico azalìdeo
NO20005421L (no) Stabile oksiderende brom formuleringer, fremgangsmåter ved fremstilling derav og fremgangsmåter ved anvendelse for mikrobiologisk vekst kontroll
BR9814104A (pt) Compostos benzeno substituìdos, processo parasua preparação e composições herbicidas edesfolhantes contendo os mesmos
PE84799A1 (es) Metodos mejorados para el procesamiento de proteina c activada
BRPI0113286B8 (pt) pirazóis substituídos e composição farmacêutica compreendendo os mesmos.
HUP0300755A2 (hu) Heparinszármazék poliszacharid keverékek, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
AU7400791A (en) Enzyme stabilizing composition and stabilized enzyme containing built detergent compositions
BR9910920A (pt) Composição não inflamável, e, processos de limpeza e de revestimento
AU2003259789A1 (en) High concentration surfactant compositions and methods
HK1047032A1 (zh) 處理解開的蛋白質表現方法的方法及產品
BR0116408A (pt) Composições de fermento lìquido
NO953644L (no) Konsentrerte rengjöringsblandinger
MX9305354A (es) Detergente liquido o en forma de gel para el lavado de vajilla que contiene alquil etoxi carboxilato, iones divalentes y alquilpolietoxipolicarboxilato.
KR860000025A (ko) 콩단백질 수용액의 처리방법
BR9808140A (pt) Formulação unitária
PT1411971E (pt) Utilizacao de pentraxina longa ptx3 para o tratamento de infertilidade feminina
BR9908763A (pt) Limpeza enzimática com bloco sólido com controle-eletrolìtico para sistemas de limpeza no local
SE8502540L (sv) Stabilt tandvardsmedel innehallande dextranas
DK0943030T3 (da) Fremgangsmåde til reduktion af svovl- og kypefarvestoffer
NO20002525D0 (no) Blanding anvendelig som overflateaktivt emulgeringsmiddel og dispersjon, fremgangsmÕte for fremstilling derav samt dets anvendelse
DK0497724T3 (da) Middel til desintegration af galdesten
SE8504774L (sv) Infattningssystem, i synnerhet for glas i brandveggar
AU2001265876A1 (en) Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application